Introduction to Pharmacovigilance
=================================

A drug is approved if the risk/benefit balance is judged to be positive for the target population in the specified indication at the time of authorization [@b1]. At that time, however, information on the safety of a medicinal product is limited due to many factors such as small numbers of patients in clinical trials; restricted population in terms of age, gender, and ethnicity; restricted comorbidity, comedications, and conditions of use; short duration of exposure and follow-up; and statistical problems associated with looking at multiple outcomes. Thus, not all actual or potential risks may be identified at the time an initial authorization is sought; many of the risks associated with the use of a medicinal product will only be discovered and characterized postauthorization with broader use.

Pharmacovigilance (PV) is defined as the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other problem related to medical products [@b2]--[@b4]. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) provide guidance to marketing authorization (license) holders for PV efforts [@b2],[@b3]. These agencies may require license holders to establish and maintain PV activities; to acquire and analyze data about adverse events and adverse drug reactions reported spontaneously by health care professionals, patients, and the public (passive surveillance); and to monitor data from registries (active surveillance) and from comparative observational or targeted clinical investigations. The type of PV surveillance activity employed will be dependent on the frequency and the specificity of the given event (Table [1](#tbl1){ref-type="table"}) [@b5]. Further investigation may be warranted if there is identification of a potential safety signal, a concern about an excess of adverse events compared to what would be expected to be associated with a product\'s use [@b3]. License holders then work with regulatory agencies to synthesize available information to continuously assess the risks and benefits, and determine the next steps (e.g., label changes, additional studies, risk management activities). Figure[1](#fig01){ref-type="fig"} provides an overview of PV concepts and activities. Health care professionals play an important role by reporting adverse events or adverse drug reactions spontaneously whenever they are observed, whether or not they believe the event is associated with a particular drug. Procedures for reporting adverse events may vary by region and country.

###### 

Strengths and limitations of different PV surveillance activities

  PV surveillance activity   Strength                                                              Limitation
  -------------------------- --------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------
  Preclinical findings       • May identify possible adverse events early                          • Needs confirmation from other PV surveillance activities
                             • May provide a mechanism for an adverse event                        
  Spontaneous reporting      • Usually the first indication of a potential safety signal           • Cannot differentiate between new safety signals or deterioration of preexisting conditions
                                                                                                   • Reporting bias
  Observational studies      • Allows rapid assessment of possible adverse events                  • Data on very rare events may not be collected or observed in databases
                             • Large sample size                                                   • Causality may be unclear
                                                                                                   • Drugs are not always used according to their label
  Clinical trials            • Prospectively tests for the presence of a potential safety signal   • Expensive
                             • Provides the highest quality of data                                • May take a long time to accumulate data
                                                                                                   • Rare events are difficult to detect due to small sample size
                                                                                                   • There may be conflicting results between individual trials due to varying trial design characteristics
  Meta-analyses              • Summarizes data from multiple trials                                • Aggregation of heterogeneous data may confound the interpretation of the results
                             • Large sample size                                                   

![Pharmacovigilance overview. After a drug is approved for use in clinical practice, assessment of its risk and benefits is a continuous process based on new data obtained through various pharmacovigilance activities. License holders work closely with regulatory agencies to analyze these data and respond with appropriate action, which might include label changes, risk mitigation activities, and required additional (safety) studies to further characterize the drug.](cam40003-1416-f1){#fig01}

Pharmacovigilance in Practice: Erythropoiesis-Stimulating Agents for Chemotherapy-Induced Anemia
================================================================================================

Erythropoiesis-stimulating agents (ESAs) are indicated for use to treat anemia in patients with cancer receiving concomitant myelosuppressive chemotherapy. Successful treatment is characterized by increases in hemoglobin levels and elimination or reduction in red blood cell transfusion requirements; some studies have also shown reduction in fatigue and improvement in quality of life [@b6],[@b7].

Two ESAs, epoetin alfa (EPOGEN, Amgen, Thousand Oaks, CA/PROCRIT, Janssen, Horsham, PA) and darbepoetin alfa (Aranesp, Amgen Inc.), are licensed in the United States for chemotherapy-induced anemia (CIA). Epoetin alfa (EPREX/ERYPO, Janssen), epoetin beta (NeoRecormonn, Roche, Welwyn Garden City, UK), epoetin theta (Eporatio, Ratiopharm, Ulm, Germany), and darbepoetin alfa (Aranesp, Amgen Inc.) are licensed in Europe for CIA. ESA biosimilars became available in Europe in 2007 (see below). The U.S. clinical and regulatory history of ESAs provides an example that demonstrates the importance of PV and the required close collaboration between license holders and regulators.

In addition to the known benefits of hemoglobin increases, transfusion reduction and possible reduction in fatigue, some early studies and meta-analyses showed a potential survival benefit and improved tumor response from use of ESAs in patients with cancer receiving chemotherapy [@b8],[@b9]. These results encouraged evaluation of ESAs in clinical studies in a wider range of indications, beyond those initially approved. The outcomes of these studies were unexpected. Starting in 2003, emerging results suggested adverse effects on survival and time to tumor progression in two large randomized controlled trials (BEST [@b10] and ENHANCE [@b11]), leading to a review of ESAs by the FDA. In contrast to the studies supporting marketing approval and labeling claims, the BEST and ENHANCE studies were specifically designed to test whether use of an ESA to achieve and maintain high hemoglobin levels (12--15 g/dL) would improve tumor outcomes and survival compared to standard supportive care [@b11],[@b12]. Instead, BEST and ENHANCE showed evidence of detrimental survival and tumor outcomes. Additional epoetin alfa trials were terminated prematurely in 2003 because of unacceptable increases in the risk of thrombotic and cardiovascular events in the ESA arm (GOG 191 [@b13], EPO-CAN-15 [@b14], PR00-03-006 [@b15]) [@b16].

In May 2004, darbepoetin alfa label warnings and precautions were revised to include new information about thrombotic events, response rate, time to progression, and overall survival. In addition, the FDA and its oncologic drug advisory committee (ODAC) met in 2004 and agreed that future studies should be randomized, double-blind, and placebo-controlled, assessing survival in a homogeneous cancer subtype, to adequately assess the risks of ESAs in the approved indications. In 2005 and 2006, license holders (in the United States, Amgen Inc. and Johnson & Johnson, New Brunswick, NJ), in collaboration with the FDA, specified ongoing ESA studies in breast [@b17]--[@b19], cervical [@b20], and small-cell lung cancer [@b21] and non-Hodgkin lymphoma [@b22] as studies that should further clarify the risk of ESAs.

In May 2007, a second ODAC meeting was requested by the FDA after results of four additional studies became available showing adverse effects on survival and tumor progression [@b23]. Study 20010103 was conducted in a heterogeneous population of patients with nonmyeloid malignancies not receiving chemotherapy [@b24]. Study 20010161 was conducted in patients with lymphoproliferative malignancies receiving chemotherapy [@b25]; adverse effects on survival had not been observed in an earlier dataset [@b26], but first became apparent after additional long-term follow-up was conducted. EPO-CAN-20 was a small quality-of-life study in patients with non--small-cell lung cancer (NSCLC) receiving radiotherapy without chemotherapy; the study was terminated prematurely [@b27]. One additional study (DAHANCA 10) in patients with head and neck cancer receiving radiotherapy clearly showed an adverse effect on time to tumor progression [@b28]. Based on the review of this new safety information, in March 2007 the FDA required license holders to revise product labeling to add a "boxed warning" describing increased risks of death, serious cardiovascular and thromboembolic events, and more rapid tumor progression. Clarification of dosing strategies was also required. One year later, a third ODAC meeting was convened by the FDA based on results of two new additional studies showing shorter survival and/or poorer loco-regional control [@b29]. The first study, PREPARE, was an open-label, randomized study comparing the efficacy of two sequential neoadjuvant chemotherapy regimens in early breast cancer patients [@b19]. An interim analysis was performed after a median follow-up of 3 years, at which time the survival rate was lower in the ESA treatment group. Additional analyses were reviewed from the second study (GOG-191) in patients with cervical cancer receiving radiochemotherapy, which had first been presented to the 2004 ODAC. Both local and distant recurrences were more frequent with ESAs; overall and progression-free survival were lower in the ESA arm versus control. In April 2008, based on the recommendation of the ODAC, the FDA required a Risk Evaluation and Mitigation Strategy (REMS) to ensure that the benefits of ESAs outweigh the risks; the REMS program was implemented in March 2010 in the United States only (Fig. [2](#fig02){ref-type="fig"}). Table [2](#tbl2){ref-type="table"} summarizes the approved EMA and FDA labels for darbepoetin alfa for CIA as of September 2013.

###### 

Approved indications for darbepoetin alfa in patients with CIA

                       U.S. prescribing information [@b6]                                                                                                                                        EU summary of product characteristics [@b7]
  -------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------
  Indication           Treatment of anemia due to the effects of concomitant myelosuppressive chemotherapy; upon initiation, there is a minimum of additional 2 months of planned chemotherapy   Treatment of symptomatic anemia in adult cancer patients with nonmyeloid malignancies receiving chemotherapy
  Limitations of use   Aranesp has not been shown to improve quality of life, fatigue, or wellbeing.                                                                                             Not applicable
                       Not indicated for use:                                                                                                                                                    
                       • For patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant chemotherapy                                  
                       • As a substitute for red blood cell transfusion for immediate correction of anemia                                                                                       
  Contraindication     • Uncontrolled hypertension                                                                                                                                               • Hypersensitivity to the active substance or to any of the excipients
                       • Pure red cell aplasia that begins after treatment with darbepoetin alfa or other erythropoietin protein drugs                                                           • Poorly controlled hypertension
                       • Serious allergic reactions to darbepoetin alfa                                                                                                                          • Poorly controlled hypertension
  Other                • Boxed warning for increased risk of death, myocardial infarction, stroke, venous thromboembolism, thrombosis of vascular access, and tumor progression or recurrence.   Effect on tumor growth listed under "Special warnings and precautions for use" (section 4.4, full Summary of Product Characteristics).
                       • REMS program in place (ESA APPRISE)[@b52]                                                                                                                               

Refer to the full U.S. prescribing information or summary of product characteristics for complete information. APPRISE, assisting providers and cancer patients with risk information for the safe use of ESAs; CIA, chemotherapy-induced anemia; ESA, erythropoiesis-stimulating agent; EU, European Union; REMS, risk evaluation and mitigation strategy.

![Regulatory history of ESAs in the United States. After approval for CIA, three FDA oncologic drug advisory meetings (ODACs) were conducted to review safety data from studies of ESAs used in patients with cancer. ESAs in cancer are currently indicated only for patients receiving concomitant chemotherapy; the U.S. label also specifies that ESAs should not be used when the anticipated treatment outcome is cure. CIA, chemotherapy-induced anemia; CT, chemotherapy; ESA, erythropoiesis-stimulating agent; FDA, Food and Drug Administration; HNSCC, head and neck squamous cell carcinoma; NSCLC, non--small-cell lung cancer; ODAC, oncology drug advisory committee; RCT, randomized controlled trial; RT, radiotherapy; SA, supplemental approval for chemotherapy-induced anemia; SCLC, small-cell lung cancer.](cam40003-1416-f2){#fig02}

Review of ESA Data in Oncology
==============================

Although more than 90 studies have been conducted on the use of ESAs in patients with cancer, most were not powered for survival analyses. Moreover, many studies tested ESAs outside of the approved label (e.g., higher trigger and/or target hemoglobin levels, with radiotherapy alone, or without chemotherapy). Because of the extent of the available data on ESAs, it might be difficult for clinicians to review all the data related to the risk/benefit balance. For this reason, meta-analyses have been conducted as part of PV efforts. By summarizing data from a large number of studies, meta-analyses of large pools of patients increase the statistical power of an analysis to identify potential safety signals that might not be evident in smaller studies [@b30]. Several meta-analyses summarize the risks and benefits of ESAs in patients with various tumor types [@b31]--[@b37] and in the subsets of patients with lung cancer [@b38] and lymphoproliferative malignancies [@b39].

In both of the tumor-specific meta-analyses, the use of ESAs was associated with a lower incidence of red blood cell transfusions [@b31]--[@b36],[@b38],[@b39]. Reduction in fatigue and improvement of quality of life were also associated with ESA use in the meta-analyses by Grant, Tonelli, Tonia, and Vansteenkiste [@b32],[@b35],[@b37],[@b38]. However, the previously observed increase in the risk of thromboembolic events was confirmed [@b31],[@b32],[@b34],[@b35],[@b38],[@b39]. When the meta-analyses included only patients with CIA, the currently approved indication, no significant effects on mortality [@b31],[@b33]--[@b36],[@b38],[@b39] or disease progression [@b34],[@b38],[@b39] were seen. However, only meta-analyses with large patient numbers [@b33],[@b34],[@b37] may have been powered to detect significant mortality differences.

Although meta-analyses have increased statistical power to identify potential safety signals, they may provide only broad, general answers on global clinical questions and may have limitations resulting from the aggregation of heterogeneous data [@b30]. Meta-analyses often incorporate populations with various tumor types, disease stages, and treatment regimens. Study design characteristics such as endpoints and statistical methods may also differ. As a result, it may be difficult for physicians to apply the general results of meta-analysis to treatment decisions for individual patients in daily clinical practice.

Results from individual studies of patients with specific tumor types have provided more focused data. Data from the postmarketing commitment studies in breast, cervical, and lung cancer and NHL showed no significant difference between ESAs and control groups for overall and progression-free survival [@b17],[@b18],[@b20]--[@b22],[@b40]. One other large randomized double-blind study in Hodgkin lymphoma also showed no significant difference in overall and progression-free survival endpoints [@b41]. In all of these studies, as expected, the incidence of transfusions was lower and the incidence of thromboembolic events was higher in the ESA groups (individual studies published since 2011 are shown in Table [3](#tbl3){ref-type="table"}) [@b17],[@b18],[@b20]--[@b22],[@b40],[@b41].

###### 

Key publications: ESA use in oncology

  Publication                                                                      Cancer type                        Cancer and anemia treatments                                                          Number of patients                                             Overall survival                                                                                                   Progression-free survival                                                                                                              RBC transfusions                                                                                                     Thromboembolic adverse events
  -------------------------------------------------------------------------------- ---------------------------------- ------------------------------------------------------------------------------------- -------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------
  Studies with reported safety signals in anemia[1](#tf3-1){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
   Leyland-Jones [@b6],[@b10] BEST Study                                           Metastatic breast cancer           First-line chemotherapy; epoetin alfa or placebo                                      939                                                            12 months: ESA: 70% Control: 76% HR 1.37 95% CI 1.07--1.75 *P* = 0.012 \[6\]                                       Disease progression at 12 months: ESA: 41% Control: 43% HR 1.00; *P* = 98 [@b10]                                                       ESA: 10% Control: 14% *P* \< 0.06 \[10\]                                                                             ESA: 16% Control: 14%
   Untch et al. [@b6],[@b19],[@b40] PREPARE Study                                  Primary breast cancer              Neoadjuvant chemotherapy; darbepoetin alfa or control                                 733                                                            3 years: ESA: 86% Control: 90% HR 1.42 95% CI 0.93--2.18 [@b6]                                                     3 years: ESA: 72% Control: 78% HR 1.33 95% CI 0.99--1.79 \[6\]                                                                         ESA: 0.3% Control: 0% [@b40]                                                                                         ESA: 6.3% Control: 4.3% [@b40]
   Thomas et al. [@b13] GOG-191 Study                                              Cervical cancer                    Chemoradiotherapy, epoetin alfa versus control                                        114                                                            3 years: ESA: 61% Control: 71% HR 1.28 95% CI 0.68--2.42 [@b6]                                                     3 years: ESA: 59% Control: 62% HR 1.06 95% CI 0.58--1.91 [@b6]                                                                         ESA: 59.6% Control: 55.8% [@b13]                                                                                     ESA: 19% Control: 9% [@b6]
   Henke et al. [@b11]                                                             Head and neck cancer               Radiotherapy; epoetin alfa versus placebo                                             351                                                            HR 1.39 95% CI 1.05--1.84 *P* = 0.02 [@b6]                                                                         ESA: 406 days Control: 745 days HR 1.62 95% CI 1.22--2.14 *P* = 0.0008 [@b6]                                                           Not reported                                                                                                         Vascular disorders: ESA: 11% Control: 5% [@b11]
   Overgaard et al. [@b28] DAHANCA 10 Study                                        Head and neck cancer               Radiotherapy; darbepoetin alfa versus control                                         522; 484 analyzed                                              RR 1.28 95% CI 0.98--1.68 *P* = 0.08 [@b6]                                                                         5 years, locoregional control RR 1.44 95% CI 1.06--1.96 *P* = 0.02 [@b6]                                                               Not reported                                                                                                         Serious cardiovascular events: ESA: 3% Control: 1% [@b28]
   Hedenus et al. [@b6],[@b25],[@b39] Study 20000161                               Lymphoproliferative malignancies   Chemotherapy; darbepoetin alfa or placebo                                             344                                                            29 months: HR 1.36 95% CI 1.02--1.82 \[6\]                                                                         Disease progression or death at 11 months ESA: 47% Control: 45%[@b25]                                                                  ESA: 31% Control: 48% *P* \< 0.001 \[25\]                                                                            ESA: 6% Control: 4% [@b39]
   Wright et al. [@b6],[@b27]                                                      NSCLC                              No systemic treatment or radiation; epoetin alfa versus placebo                       70                                                             ESA: 63 days Control: 129 days HR 1.84; *P* = 0.04 \[6\]                                                           Not reported                                                                                                                           ESA: 15% Control: 27% [@b27]                                                                                         ESA: 3% Control: 5% \[27\]
   Smith et al. [@b6],[@b53]                                                       Nonmyeloid malignancies            Neither chemotherapy nor radiotherapy; darbepoetin alfa versus placebo                989                                                            ESA: 8 months Control: 10.8 months HR 1.30 95% CI 1.07--1.57 [@b6],[@b21]                                          Not reported                                                                                                                           ESA: 19% Control: 24% [@b53]                                                                                         ESA: 2.3% Control: 1.5% [@b53]
  Meta-analyses published since 2009                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
   Ludwig et al. [@b31]                                                            Various tumor types                Chemotherapy; darbepoetin alfa or placebo                                             2122                                                           HR 0.97 95% CI 0.85--1.10                                                                                          HR 0.83 95% CI 0.84--1.04                                                                                                              Not reported                                                                                                         ESA: 8% Control: 5% HR 1.57 95% CI 1.10--2.26
   Tonelli et al. [@b32]                                                           Various tumor types                Chemotherapy, surgery, radiotherapy, or no cancer treatment; any ESA or control       12,006                                                         All patients: RR 1.15 95% CI 1.03--1.29 Patients receiving chemotherapy: RR 1.04 95% CI 0.86--1.26                 Not reported                                                                                                                           RR 0.64 95% CI 0.56--0.73                                                                                            Cardiovascular events: RR 1.12 95% CI 0.83--1.50
   Bohlius et al. [@b54] (Cochrane analysis)                                       Various tumor types                Chemotherapy, radiotherapy, or no cancer treatment; any ESA with or without control   13,933                                                         All patients: cHR 1.06 95% CI 1.00--1.12 *P* = 0.046 Patients receiving chemotherapy: cHR 1.04 95% CI 0.97--1.11   Not reported                                                                                                                           Not reported                                                                                                         Not reported
   Glaspy et al. [@b34]                                                            Various tumor types                Chemotherapy, radiotherapy, or no cancer treatment; any ESA with or without control   All patients: 15,323 Patients receiving chemotherapy: 12,108   All patients: OR 1.06 95% CI 0.97--1.15 Patients receiving chemotherapy: OR 1.03 95% CI 0.93--1.13                 All patients: OR 1.01 95% CI 0.90--1.14 Patients receiving chemotherapy: OR 0.94 95% CI 0.85--1.06                                     Not reported                                                                                                         OR 1.48 95% CI 1.28--1.72
   Tonia et al. [@b35] (Cochrane analysis)                                         Various tumor types                Chemotherapy subset analyses; any ESA with or without control                         All patients: 20,102 Patients receiving chemotherapy: 13,800   All patients: HR 1.05 95% CI 1.0--1.11 Patients receiving chemotherapy: HR 1.04 95% CI 0.98--1.11                  Not reported                                                                                                                           All patients: RR 0.65 95% CI 0.62--0.68 Patients receiving chemotherapy: RR 0.64 95% CI 0.61--0.67                   All patients: RR 1.52 95% CI 1.34--1.74 Patients receiving chemotherapy: RR 1.48 95% CI 1.27--1.73
   Vansteenkiste et al. [@b38]                                                     Lung cancer (NSCLC and SCLC)       Chemotherapy, radiotherapy, combination, or none; any ESA or control                  2342                                                           Study-level analysis: OR 0.87 95% CI 0.69--1.09 Patient-level analysis: HR 0.90 95% CI 0.78--1.03                  Study-level analysis: OR 0.84 95% CI 0.65--1.09 Patient-level analysis: HR 0.92 95% CI 0.81--1.06                                      Week 5 to end of study Study-level analysis OR 0.34 95% CI 0.29--0.41 Patient-level analysis: ESA 19% Control: 43%   ESA: 10.5% Control: 7.2%
   Hedenus et al. [@b39]                                                           Lymphoproliferative malignancies   Chemotherapy; any ESA or control                                                      2866                                                           OR 1.05 95% CI 0.81--1.34                                                                                          OR 1.02 95% CI 0.81--1.30                                                                                                              Individual study data: ESA: 19--63% Control: 28--82%                                                                 Individual study data: ESA: 3--9% Control: 0--4%
   Grant et al. [@b37]                                                             Various tumor types                Chemotherapy, radiotherapy, combination, or none; any ESA or control                  14,278                                                         RR 1.04 95% CI 0.99--1.10                                                                                          Not reported                                                                                                                           RR 0.58 95% CI 0.53--0.64                                                                                            RR 1.51 95% CI 1.30--1.74
  Individual studies published since 2011                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
   Blohmer et al. [@b20]                                                           High-risk cervical cancer          Chemotherapy; epoetin alfa or control                                                 257                                                            HR 0.88 95% CI 0.51--1.50                                                                                          HR 0.66 95% CI 0.39--1.12                                                                                                              ESA: 10.7% Control: 29.6% *P* \< 0.001                                                                               ESA: 1.6% Control: 2.4%
   Möbus et al. [@b17]                                                             Node-positive breast cancer        Chemotherapy; epoetin alfa or control                                                 1284                                                           5 years: HR 0.97 95% CI 0.67--1.41 *P* = 0.89                                                                      5 years: HR 1.03 95% CI 0.77--1.37 *P* = 0.86                                                                                          ESAs: 12.8% Control: 28.1% *P* \< 0.0001                                                                             ESA: 7% Control: 3%
   Delarue et al. [@b22],[2](#tf3-2){ref-type="table-fn"} LNH03-6B Study           Diffuse large B-cell lymphoma      Chemotherapy; darbepoetin alfa or standard of care                                    600                                                            HR 0.81 95% CI 0.60--1.09 *P* = 0.16                                                                               3 years: Progression-free survival: HR 0.77 95% CI 0.59--0.99 *P* = 0.04 Disease-free survival: HR 0.65 95% CI 0.45--0.92 *P* = 0.02   Not reported                                                                                                         ESA: 13% Control: 6%
  Ongoing safety studies                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
   Study EPO-ANE-3010 [@b42]                                                       Metastatic breast cancer           Chemotherapy; epoetin alfa or standard of care                                        Estimate 2100                                                  No data yet reported; estimated completion date 2017                                                                                                                                                                                                                                                                                                                           
   Study 20070782 [@b43]                                                           Metastatic NSCLC                   Chemotherapy; darbepoetin alfa or placebo                                             Estimate 3000                                                  No data yet reported; estimated completion date 2019                                                                                                                                                                                                                                                                                                                           

Control refers to placebo or standard of care as reported in each study. A hazard ratio, rate ratio, or odds ratio less than 1 favors ESAs; a value greater than 1 favors control. ESA, erythropoiesis-stimulating agent; HR, hazard ratio; CI, confidence interval; OR, odds ratio; RR, rate ratio; cHR, combined hazard ratio; NSCLC, non--small-cell lung cancer; SCLC, small-cell lung cancer.

For studies cited in product labels, data from the label were used when available; otherwise, data from publications were used as cited.

In the Delarue study, 40% of patients in the control arm received ESAs and this may limit the ability to detect differences between the experimental and the control arm. Results reported are for treatment groups as randomized for consistency with other results presented here.

Ongoing Safety Studies With ESA for Chemotherapy-Induced Anemia
===============================================================

As part of ongoing PV efforts to characterize the safety profile of ESAs, two large randomized, multicenter studies are ongoing and enrolling patients globally (Fig.[3](#fig03){ref-type="fig"}). These studies were specifically designed in collaboration with regulatory agencies to evaluate if the use of ESA *as indicated* has an adverse effect on survival in patients with CIA. Both studies have a noninferiority design and are adequately powered for survival endpoints. EPO-ANE-3010 [@b42] is a randomized, open-label study of weekly epoetin alfa plus standard supportive care (red blood cell transfusions) versus standard supportive care alone in approximately 2100 anemic patients with metastatic breast cancer receiving chemotherapy. The study\'s primary endpoint is progression-free survival. Secondary endpoints include overall survival, time to tumor progression, and overall response rate. Results are expected in 2017. Study 20070782 [@b43] is a randomized, double-blind, placebo-controlled study of darbepoetin alfa every 3 weeks versus placebo in approximately 3000 anemic patients with metastatic non--small-cell lung cancer (NSCLC) receiving chemotherapy. A total of 2700 deaths are required to exclude a hazard ratio (darbepoetin alfa:placebo) of 1.15 with a one-sided significance level of 0.025 (the study is powered at over 90% if the true hazard ratio is 1.00). The primary endpoint is overall survival; secondary endpoints include progression-free survival, objective tumor response, and incidence of thromboembolic adverse events. Results are expected in 2019.

![Ongoing safety studies in metastatic breast cancer and non--small-cell lung cancer [@b42],[@b43]. NSCLC, non--small-cell lung cancer; SC, subcutaneous.](cam40003-1416-f3){#fig03}

ESA for Chemotherapy-Induced Anemia: Guidelines
===============================================

Guidelines are regularly updated by several organizations involved in the care of patients with cancer to reflect current evidence [@b44]--[@b47]. These guidelines may be useful in evaluating treatment options. Table [4](#tbl4){ref-type="table"} summarizes current U.S. and European guidelines for the treatment of anemia in patients with cancer.

###### 

Use of ESAs in CIA: published guidelines as of 2013

  Guidelines                                 National Cancer Care Network (NCCN) [@b45]                                                                           American Society of Clinical Oncology (ASCO) and American Society of Hematology (ASH) (joint guidelines) [@b46]   European Society for Medical Oncology (ESMO) [@b47]                                    European Organization for Research and Treatment of Cancer (EORTC) [@b44]
  ------------------------------------------ -------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------
  Hemoglobin level for diagnosis of anemia   \<10 g/dL                                                                                                            \<10 g/dL                                                                                                         ≤10 g/dL                                                                               9.0--11.0 g/dL based on anemia symptoms 11.0--11.9 g/dL for selected patients to prevent further decline
  Target hemoglobin level                    Lowest level that avoids transfusion                                                                                 Lowest level that avoids transfusion                                                                              Not exceed 12 g/dL                                                                     About 12 g/dL
  Indication/Initiation                      • Only to be administered under REMS program (ESA APPRISE) as indicated by U.S. prescribing information              • Patients undergoing myelosuppressive chemotherapy to decrease transfusions                                      • Treatment of symptomatic CIA in nonmyeloid malignancies.                             • Patients receiving chemotherapy or radiochemotherapy
                                             • For anemia with myelosup-pressive chemotherapy without other identifiable cause of anemia, ESA may be considered   • Not for curative intent                                                                                         • Use with caution with chemotherapy with curative intent                              • Not for prophylaxis
                                             • In anemic patients undergoing palliative treatment, ESA may be considered                                                                                                                                                                                                                                                   
                                             • Should not be used if the anticipated outcome is cure                                                                                                                                                                                                                                                                       
  Iron supplementation                       Patients receiving ESA developing functional iron deficiency will likely benefit from IV iron                        Insufficient evidence to consider the use of IV iron as standard of care                                          IV iron leads to higher Hb increment in comparison with oral or no iron substitution   There is evidence of better response to ESAs with IV iron

Hb, hemoglobin; IV, intravenous; RBC, red blood cell; REMS, Risk Evaluation and Mitigation Strategy.

Biosimilars and PV
==================

Since 2007, biosimilars to epoetin alfa have become available in Europe, including three brands of epoetin alfa: Hexal (Hexal, Holzkirchen, Germany), Abseamed (Medice Arzneimittel Pütter, Iserlohn Germany), and Binocrit (Sandoz, Kundl, Austria), and two brands of epoetin zeta: Retacrit (Hospira, Warwickshire, UK) and Silapo (Stada, Bad Vilbel, Germany) [@b48]. Biosimilars are subject to regulatory reviews different from those implemented for either innovator or generic drugs. The importance of PV activities has recently been underscored by reports of immunogenicity with biosimilars of epoetin alfa administered subcutaneously in chronic kidney disease [@b49]. Aggregation of proteins caused by devices in use (e.g., tungsten exposure in prefilled syringes [@b50]), formulations (e.g., replacement of the stabilizer human-sourced albumin with polysorbate 80 [@b51]), or inappropriate handling discovered in these situations strongly supports the need for robust PV programs for biosimilars including long-term follow-up of patients included in clinical trials.

Summary
=======

PV is the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects related to licensed medical products. ESAs are used to treat anemia in patients with cancer receiving concomitant myelosuppressive chemotherapy; the history of ESA use in the United States provides an example of PV and its application to a medical product. In the early postapproval period, results of studies performed outside of the approved indications suggested that ESAs were associated with an increased risk of adverse outcomes. PV efforts including meta-analyses and individual studies helped to characterize this risk. Clinical studies have consistently confirmed that ESAs increase hemoglobin and reduce the need for transfusions, but also that they increase the risk of thromboembolic adverse events. No significant effect of ESAs on survival or disease progression has been shown in studies within the approved indication of patients with CIA. Two large randomized trials in breast cancer and NSCLC are ongoing and enrolling patients globally; results of these studies in the next 5--7 years will further clarify the risks and benefits of ESAs when used in accordance with product labeling.

Conclusions
===========

Robust PV programs are an essential and continuing effort; new data are continuously being evaluated to ensure that drugs are safe for their indicated uses. Ongoing studies are expected to shed additional light on the effects of ESAs on survival and disease progression in patients with chemotherapy-induced anemia.
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